

08 APR 2005

#3



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Virginia G. Campen
GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709

In re Application of :
BACUS et al. :
Application No.: 10/529,922 :
PCT No.: PCT/US03/12739 :
Int. Filing Date: 24 April 2003 :
Priority Date: 19 June 2002 :
Attorney Docket No.: PU4995USW :
For: PREDICTIVE MARKERS IN CANCER :
THERAPY :


DECISION ON PETITION
UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 30 March 2005 in the above-captioned application is hereby GRANTED as follows:

Applicants' statement that "the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicants have submitted the basic national fee and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being returned to the United States Designated/Elected Office for processing in accordance with this decision.


Anthony Smith
Attorney-Advisor
Office PCT Legal Administration
Tel.: 571-272-3298
Facsimile: 571-273-0459